ArticleJournal of family & community medicine
Her4 in gastric adenocarcinoma and its association with molecular prognostic markers Ki-67 proliferation index and p53 mutational status in Saudis: A study at a tertiary care hospital in Eastern Saudi Arabia.
Article in Journal of family & community medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is the fifth most common and third leading cause of cancer death worldwide. Her4 receptor has proapoptotic and antiproliferative activity. The role of Her4 in gastric carcinogenesis and its prognostic implications have not been much investigated, as evidenced by the paucity of overall and Saudi regional-based studies. This study aimed to highlight the expression of Her4 in gastric adenocarcinoma (GA) as well as its association with clinicopathological parameters and molecular prognostic markers Ki-67 and p53 in a Saudi cohort. MATERIALS AND
methodsIn this descriptive cross-sectional study, data were retrospectively obtained by selecting all cases of GA from 2012 to 2022, for which Her4 immunohistochemical (IHC) analysis was done by total population sampling technique from the Pathology Department archives of King Fahd Hospital of the University, Al-Khobar, Saudi Arabia. Patients' demographic and clinicopathological profile, Lauren's histological classification, and IHC data for Ki-67, p53, and Her2-neu were also retrieved. Her4 positivity was recalibrated and its association with clinicopathological parameters, Ki-67, p53 and Her2-neu was determined. Data analysis performed using SPSS; Chi-square test assessed the relationship between Ki-67 proliferation index and p53 mutation status in Her4-negative cases.
resultsOut of the 50 cases of GA selected, Her4-positive cases were 22% (
conclusionHer4 frequency of 22% is lower than other reported studies underlining the concept of geographical and ethnic variation in intrinsic tumor properties. Her4 expression with a higher tumor grade, high Ki-67 proliferation index, and aberrant/mutational p53 status imparts an aggressive tumor characteristic to this set of GA cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.